Click "OK" to leave this site and learn about additional Novo Nordisk treatments for your patients with hemophilia. Click "Cancel" to stay and learn more about how Noveight® may be right for your patients.
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery
Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery
Novo Nordisk, Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Esperoct® and Novoeight® are registered trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2020 Novo Nordisk All rights reserved. US20NEGT00010 November 2020
If you like the efficacy and fixed dosing of Novoeight (antihemophilic factor, recombinant), take a look at Esperoct® for your hemophilia A patients. With a longer half-life across age groups than standard half-life FVIII products, Esperoct® could be right for your patients.1,a,b
aA phase 1, open-label study evaluated the safety and pharmacokinetic properties of Esperoct® in 26 PTPs. Patients received a single dose of 25, 50, or 75 IU/kg of their previous SHL product (pdFVIII or rFVIII), followed by the same dose of Esperoct®. To allow for comparison, all results were adjusted to a 50 IU/kg dose of each product.1
bIn a phase 3 study of children (aged <12 years) a single-dose PK comparison was performed in 27 children between previous SHL products and Esperoct® at the same administered dose prior to the start of routine prophylaxis. Half-life comparison is based upon the estimated half-life derived from a population-based model. During the main phase, 68 children received prophylaxis at an average dose of approximately 65 IU/kg twice weekly for 26 weeks.2